Why Corcept Therapeutics Incorporated (CORT) stock moved
Corcept Therapeutics Incorporated (CORT) shares rose 1.9% to $92.28 as of July 20, 2026, a modest gain from the prior close of $90.52. BestStocks flagged the session as a major change for CORT. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for CORT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CORT climbed 1.9% to $92.28
CORT rose 1.9% in its latest session, moving from $90.52 to $92.28.
What it means for Corcept Therapeutics Incorporated investors
For Corcept Therapeutics Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.9% session move; Corcept Therapeutics Incorporated (CORT) moved +5.32% from $85.90 to $90.47 on 2026-07-14. Weighing against that: Corcept Therapeutics Incorporated (CORT) moved -6.51% from $91.88 to $85.90 on 2026-07-13; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $104.50, implying +13.2% upside from $92.28. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 10 days out, the next report is the most likely near-term test of the move.
CORT price reaction
CORT last traded at $92.28, up $1.76 (+1.94%) from the previous close of $90.52. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $79.71 and $94.04, and it currently sits about 88% of the way up that band.
Bullish and bearish analyst opinions on Corcept Therapeutics Incorporated (CORT)
The consensus analyst price target on Corcept Therapeutics Incorporated (CORT) is $104.50, 13.2% above the recent $92.28. Over the past 90 days analysts logged 1 upgrade, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CORT line up.
The bullish case
- Wall Street's consensus price target of $104.50 implies +13.2% upside from $92.28.
- The Street's most bullish target is $135.00 (+46.3%).
- 1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-05-13).
- Positive 1.9% session move.
- Corcept Therapeutics Incorporated (CORT) moved +5.32% from $85.90 to $90.47 on 2026-07-14.
The bearish case
- The most bearish analyst target is $88.00 (-4.6%).
- Corcept Therapeutics Incorporated (CORT) moved -6.51% from $91.88 to $85.90 on 2026-07-13.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CORT
Frequently asked questions about CORT
Why did Corcept Therapeutics Incorporated (CORT) stock move?
CORT rose 1.9% to $92.28. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CORT stock rise?
CORT gained 1.94% ($1.76) versus the prior close of $90.52, last trading at $92.28 on 0.4× average volume.
When is Corcept Therapeutics Incorporated's next earnings date?
CORT's next earnings report is estimated for 2026-07-30 — about 10 days away.
What is the analyst price target for CORT?
The consensus analyst price target for CORT is $104.50, about 13.2% above the current $92.28. Over the past 90 days, analysts recorded 1 upgrade, 4 maintains, and 0 downgrades.
How BestStocks tracks CORT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CORT-specific materiality thresholds, triggering an evidence check. It draws on 7 tracked change events for CORT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.